{"transactions":[{"id":729196,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729195,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729194,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729193,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15230,"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":901160,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T00:55:20.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":17126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date."}],"balance_after":17126,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":17126},"source":{"system":"sec-edgar","filing":"0001805097-26-000001","document":"form4-02182026_120215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000180509726000001/form4-02182026_120215.xml","form_type":"4"}},{"id":1067860,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-08-13T20:55:50.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2302},"source":{"system":"sec-edgar","filing":"0001439222-25-000098","document":"wk-form4_1755118547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922225000098/wk-form4_1755118547.xml","form_type":"4"}},{"id":1067859,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-08-13T20:55:50.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12414,"source":{"system":"sec-edgar","filing":"0001439222-25-000098","document":"wk-form4_1755118547.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922225000098/wk-form4_1755118547.xml","form_type":"4"}},{"id":1103881,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-06-23T20:27:14.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-25-000061","document":"wk-form4_1750710427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922225000061/wk-form4_1750710427.xml","form_type":"4"}},{"id":1103880,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-06-23T20:27:14.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":15768,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026."}],"balance_after":15768,"derivative":{"exercise_price":35.5,"expiration_date":"2035-06-18","underlying":"Common stock","underlying_shares":15768},"source":{"system":"sec-edgar","filing":"0001439222-25-000061","document":"wk-form4_1750710427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922225000061/wk-form4_1750710427.xml","form_type":"4"}},{"id":1103879,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-06-23T20:27:14.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2816,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-25-000061","document":"wk-form4_1750710427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922225000061/wk-form4_1750710427.xml","form_type":"4"}},{"id":1103878,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-06-23T20:27:14.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10112,"source":{"system":"sec-edgar","filing":"0001439222-25-000061","document":"wk-form4_1750710427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922225000061/wk-form4_1750710427.xml","form_type":"4"}},{"id":1276677,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:33:23.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":20491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":20491,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":20491},"source":{"system":"sec-edgar","filing":"0001415889-25-003516","document":"form4-02102025_100220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588925003516/form4-02102025_100220.xml","form_type":"4"}},{"id":1369093,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-08","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":17947,"derivative":{"exercise_price":25.99,"expiration_date":"2032-08-11","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369092,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-07","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":27947,"derivative":{"exercise_price":25.99,"expiration_date":"2032-08-11","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369091,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-08","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":59.21,"value":88815.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.01 to $59.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7992,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369090,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-08","kind":"sale","planned":true,"acquired":false,"shares":4929,"price":58.57,"value":288691.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.00 to $58.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":9492,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369089,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-08","kind":"sale","planned":true,"acquired":false,"shares":3571,"price":57.24,"value":204404.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.00 to $58.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":14421,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369088,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-08","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":25.99,"value":259900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17992,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369087,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":1868,"price":54.41,"value":101637.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.02 to $54.60. The reporting person undertakes, upon request by the staff of the\nSecurities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7992,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369086,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":8132,"price":53.32,"value":433598.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.00 to $53.84. The reporting person undertakes, upon request by the staff of the\nSecurities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":9860,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1369085,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-12T21:09:38.000Z","date":"2024-11-07","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":25.99,"value":259900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17992,"source":{"system":"sec-edgar","filing":"0001439222-24-000142","document":"wk-form4_1731445769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000142/wk-form4_1731445769.xml","form_type":"4"}},{"id":1388143,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-11T00:36:22.000Z","date":"2024-10-08","kind":"exercise","planned":true,"acquired":false,"shares":4106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 32,849 shares, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter."}],"balance_after":12322,"derivative":{"exercise_price":5.52,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":4106},"source":{"system":"sec-edgar","filing":"0001415889-24-024990","document":"form4-10112024_121018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924024990/form4-10112024_121018.xml","form_type":"4"}},{"id":1388142,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-11T00:36:22.000Z","date":"2024-10-08","kind":"exercise","planned":true,"acquired":false,"shares":6314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":69428,"derivative":{"exercise_price":19.68,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":6314},"source":{"system":"sec-edgar","filing":"0001415889-24-024990","document":"form4-10112024_121018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924024990/form4-10112024_121018.xml","form_type":"4"}},{"id":1388141,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T00:36:22.000Z","date":"2024-10-08","kind":"sale","planned":true,"acquired":false,"shares":10420,"price":28.1725,"value":293557.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.00 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":22341,"source":{"system":"sec-edgar","filing":"0001415889-24-024990","document":"form4-10112024_121018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924024990/form4-10112024_121018.xml","form_type":"4"}},{"id":1388140,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T00:36:22.000Z","date":"2024-10-08","kind":"exercise","planned":true,"acquired":true,"shares":4106,"price":5.52,"value":22665.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":32761,"source":{"system":"sec-edgar","filing":"0001415889-24-024990","document":"form4-10112024_121018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924024990/form4-10112024_121018.xml","form_type":"4"}},{"id":1388139,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T00:36:22.000Z","date":"2024-10-08","kind":"exercise","planned":true,"acquired":true,"shares":6314,"price":19.68,"value":124259.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":28655,"source":{"system":"sec-edgar","filing":"0001415889-24-024990","document":"form4-10112024_121018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924024990/form4-10112024_121018.xml","form_type":"4"}},{"id":1434888,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-08-13T20:15:37.000Z","date":"2024-08-11","kind":"exercise","planned":false,"acquired":false,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2302,"derivative":{"underlying":"Common stock","underlying_shares":2302},"source":{"system":"sec-edgar","filing":"0001439222-24-000127","document":"wk-form4_1723580129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000127/wk-form4_1723580129.xml","form_type":"4"}},{"id":1434887,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-08-13T20:15:37.000Z","date":"2024-08-11","kind":"exercise","planned":false,"acquired":true,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7992,"source":{"system":"sec-edgar","filing":"0001439222-24-000127","document":"wk-form4_1723580129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000127/wk-form4_1723580129.xml","form_type":"4"}},{"id":1470753,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2024-06-24T20:10:23.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":11774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025."}],"balance_after":11774,"derivative":{"exercise_price":42.45,"expiration_date":"2034-06-20","underlying":"Common stock","underlying_shares":11774},"source":{"system":"sec-edgar","filing":"0001439222-24-000106","document":"wk-form4_1719259815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000106/wk-form4_1719259815.xml","form_type":"4"}},{"id":1470752,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-24T20:10:23.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2120,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-24-000106","document":"wk-form4_1719259815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000106/wk-form4_1719259815.xml","form_type":"4"}},{"id":1477386,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-17T21:22:51.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":false,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-24-000085","document":"wk-form4_1718659363.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000085/wk-form4_1718659363.xml","form_type":"4"}},{"id":1477385,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-06-17T21:22:51.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5690,"source":{"system":"sec-edgar","filing":"0001439222-24-000085","document":"wk-form4_1718659363.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922224000085/wk-form4_1718659363.xml","form_type":"4"}},{"id":1542628,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":false,"shares":4580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":75742,"derivative":{"exercise_price":19.68,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":4580},"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542627,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":false,"shares":48820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":12.6,"expiration_date":"2028-10-19","underlying":"Common Stock","underlying_shares":48820},"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542626,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-10","kind":"exercise","planned":true,"acquired":false,"shares":13600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":48820,"derivative":{"exercise_price":12.6,"expiration_date":"2028-10-19","underlying":"Common Stock","underlying_shares":13600},"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542625,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":3068,"price":25.2094,"value":77342.4392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $25.02 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":22341,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542624,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":20032,"price":24.9951,"value":500701.8432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $24.015 to $25.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":25409,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542623,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":30300,"price":23.1361,"value":701023.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $23.00 to $23.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":45441,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542622,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":true,"shares":4580,"price":19.68,"value":90134.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":75741,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542621,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":true,"shares":48820,"price":12.6,"value":615132.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":71161,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542620,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-10","kind":"sale","planned":true,"acquired":false,"shares":13600,"price":21.0106,"value":285744.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $21.00 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":22341,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1542619,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-12T22:23:49.000Z","date":"2024-04-10","kind":"exercise","planned":true,"acquired":true,"shares":13600,"price":12.6,"value":171360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":35941,"source":{"system":"sec-edgar","filing":"0001415889-24-010777","document":"form4-04122024_100442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010777/form4-04122024_100442.xml","form_type":"4"}},{"id":1545794,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-09T00:40:47.000Z","date":"2024-04-04","kind":"exercise","planned":true,"acquired":false,"shares":3485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":62420,"derivative":{"exercise_price":12.6,"expiration_date":"2028-10-19","underlying":"Common Stock","underlying_shares":3485},"source":{"system":"sec-edgar","filing":"0001415889-24-010520","document":"form4-04092024_120438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010520/form4-04092024_120438.xml","form_type":"4"}},{"id":1545793,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-09T00:40:47.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":3485,"price":19.1476,"value":66729.386,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $19.05 to $19.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":22341,"source":{"system":"sec-edgar","filing":"0001415889-24-010520","document":"form4-04092024_120438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010520/form4-04092024_120438.xml","form_type":"4"}},{"id":1545792,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-09T00:40:47.000Z","date":"2024-04-04","kind":"exercise","planned":true,"acquired":true,"shares":3485,"price":12.6,"value":43911.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":25826,"source":{"system":"sec-edgar","filing":"0001415889-24-010520","document":"form4-04092024_120438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010520/form4-04092024_120438.xml","form_type":"4"}},{"id":1549917,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T01:32:05.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":3143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the \"Stock Split\")."}],"balance_after":16428,"derivative":{"exercise_price":5.52,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":3143},"source":{"system":"sec-edgar","filing":"0001415889-24-010232","document":"form4-04042024_010458.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010232/form4-04042024_010458.xml","form_type":"4"}},{"id":1549916,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T01:32:05.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":94,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the \"Stock Split\")."}],"balance_after":65905,"derivative":{"exercise_price":12.6,"expiration_date":"2028-10-19","underlying":"Common Stock","underlying_shares":94},"source":{"system":"sec-edgar","filing":"0001415889-24-010232","document":"form4-04042024_010458.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010232/form4-04042024_010458.xml","form_type":"4"}},{"id":1549915,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T01:32:05.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":3237,"price":19.0789,"value":61758.3993,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $19.00 to $19.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":22341,"source":{"system":"sec-edgar","filing":"0001415889-24-010232","document":"form4-04042024_010458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010232/form4-04042024_010458.xml","form_type":"4"}},{"id":1549914,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T01:32:05.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":3143,"price":5.52,"value":17349.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":25578,"source":{"system":"sec-edgar","filing":"0001415889-24-010232","document":"form4-04042024_010458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010232/form4-04042024_010458.xml","form_type":"4"}},{"id":1549913,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T01:32:05.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":94,"price":12.6,"value":1184.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":22435,"source":{"system":"sec-edgar","filing":"0001415889-24-010232","document":"form4-04042024_010458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924010232/form4-04042024_010458.xml","form_type":"4"}},{"id":1563518,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T23:46:23.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":false,"shares":13278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the \"Stock Split\") and (ii) has been adjusted following an internal review of the Reporting Person's holdings."}],"balance_after":19571,"derivative":{"exercise_price":5.52,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":13278},"source":{"system":"sec-edgar","filing":"0001415889-24-009019","document":"form4-03222024_110316.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924009019/form4-03222024_110316.xml","form_type":"4"}},{"id":1563517,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T23:46:23.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":13278,"price":19.1642,"value":254462.2476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $19.005 to $19.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":22341,"source":{"system":"sec-edgar","filing":"0001415889-24-009019","document":"form4-03222024_110316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924009019/form4-03222024_110316.xml","form_type":"4"}},{"id":1563516,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T23:46:23.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":13278,"price":5.52,"value":73294.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the \"Stock Split\") and (ii) has been adjusted following an internal review of the Reporting Person's holdings."}],"balance_after":35619,"source":{"system":"sec-edgar","filing":"0001415889-24-009019","document":"form4-03222024_110316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924009019/form4-03222024_110316.xml","form_type":"4"}},{"id":1634006,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-21T00:24:06.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":23364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."}],"balance_after":23364,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":23364},"source":{"system":"sec-edgar","filing":"0001415889-24-004482","document":"form4a-02212024_120256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924004482/form4a-02212024_120256.xml","form_type":"4/A","original_submission_date":"2024-02-15"}},{"id":1641118,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T01:41:49.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":16835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":16835,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":16835},"source":{"system":"sec-edgar","filing":"0001415889-24-004006","document":"form4-02162024_010242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000141588924004006/form4-02162024_010242.xml","form_type":"4"}},{"id":1807408,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-08-15T20:06:44.000Z","date":"2023-08-11","kind":"exercise","planned":false,"acquired":false,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":4604,"derivative":{"underlying":"Common stock","underlying_shares":2302},"source":{"system":"sec-edgar","filing":"0001439222-23-000129","document":"wk-form4_1692129995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922223000129/wk-form4_1692129995.xml","form_type":"4"}},{"id":1807407,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-08-15T20:06:44.000Z","date":"2023-08-11","kind":"exercise","planned":false,"acquired":true,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2302,"source":{"system":"sec-edgar","filing":"0001439222-23-000129","document":"wk-form4_1692129995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922223000129/wk-form4_1692129995.xml","form_type":"4"}},{"id":1854519,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2023-06-15T20:25:20.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":18958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024."}],"balance_after":18958,"derivative":{"exercise_price":26.56,"expiration_date":"2033-06-13","underlying":"Common stock","underlying_shares":18958},"source":{"system":"sec-edgar","filing":"0001439222-23-000079","document":"wk-form4_1686860710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922223000079/wk-form4_1686860710.xml","form_type":"4"}},{"id":1854518,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-06-15T20:25:20.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":3388,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-23-000079","document":"wk-form4_1686860710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922223000079/wk-form4_1686860710.xml","form_type":"4"}},{"id":1923828,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:15:40.000Z","date":"2023-02-23","kind":"grant","planned":false,"acquired":true,"shares":27567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":27567,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":27567},"source":{"system":"sec-edgar","filing":"0001209191-23-023661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919123023661/doc4.xml","form_type":"4"}},{"id":2000070,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-23T01:25:50.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":32861,"price":4.66,"value":153132.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":87835,"source":{"system":"sec-edgar","filing":"0001209191-23-012015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919123012015/doc4.xml","form_type":"4"}},{"id":2038605,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-01T23:24:19.000Z","date":"2023-01-30","kind":"sale","acquired":false,"shares":11313,"price":3.91,"value":44233.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":120696,"source":{"system":"sec-edgar","filing":"0001209191-23-005993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919123005993/doc4.xml","form_type":"4"}},{"id":2185726,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2022-08-15T22:31:23.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":6906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":6906,"derivative":{"underlying":"Common stock","underlying_shares":6906},"source":{"system":"sec-edgar","filing":"0001439222-22-000084","document":"wf-form4_166060255599985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922222000084/wf-form4_166060255599985.xml","form_type":"4"}},{"id":2185725,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-08-15T22:31:23.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":37947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":37947,"derivative":{"exercise_price":25.99,"expiration_date":"2032-08-11","underlying":"Common stock","underlying_shares":37947},"source":{"system":"sec-edgar","filing":"0001439222-22-000084","document":"wf-form4_166060255599985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922222000084/wf-form4_166060255599985.xml","form_type":"4"}},{"id":2419431,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-01T22:02:56.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":131400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":131400,"derivative":{"exercise_price":1.38,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":131400},"source":{"system":"sec-edgar","filing":"0001209191-22-005942","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919122005942/doc4.xml","form_type":"4"}},{"id":2419430,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-01T22:02:56.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":131400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date."}],"balance_after":137009,"source":{"system":"sec-edgar","filing":"0001209191-22-005942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919122005942/doc4.xml","form_type":"4"}},{"id":2888844,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-01T21:44:16.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":133350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":133350,"derivative":{"exercise_price":13.05,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":133350},"source":{"system":"sec-edgar","filing":"0001209191-21-006453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919121006453/doc4.xml","form_type":"4"}},{"id":2936358,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-21T21:47:04.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":4999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on October 19, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on May 29, 2019 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":263999,"derivative":{"exercise_price":3.15,"expiration_date":"2028-10-18","underlying":"Common Stock","underlying_shares":4999},"source":{"system":"sec-edgar","filing":"0001209191-20-064659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919120064659/doc4.xml","form_type":"4"}},{"id":2936357,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-21T21:47:04.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":4999,"price":25,"value":124975.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Ballal's trading plan under Rule 10b5-1."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-064659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919120064659/doc4.xml","form_type":"4"}},{"id":2936356,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-21T21:47:04.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":4999,"price":3.15,"value":15746.85,"ownership":{"direct":true},"balance_after":4999,"source":{"system":"sec-edgar","filing":"0001209191-20-064659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919120064659/doc4.xml","form_type":"4"}},{"id":2942866,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-16T21:15:02.000Z","date":"2020-12-14","kind":"exercise","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on October 19, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on May 29, 2019 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":268998,"derivative":{"exercise_price":3.15,"expiration_date":"2028-10-18","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001209191-20-063780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919120063780/doc4.xml","form_type":"4"}},{"id":2942865,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-16T21:15:02.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":1,"price":25,"value":25.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Ballal's trading plan under Rule 10b5-1."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-063780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919120063780/doc4.xml","form_type":"4"}},{"id":2942864,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-16T21:15:02.000Z","date":"2020-12-14","kind":"exercise","acquired":true,"shares":1,"price":3.15,"value":3.15,"ownership":{"direct":true},"balance_after":1,"source":{"system":"sec-edgar","filing":"0001209191-20-063780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000120919120063780/doc4.xml","form_type":"4"}}]}